Researchers Suggest SARS-CoV-2 Disease Burden May Be Much Larger Due to Underreporting

Estimates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease burden are needed to help guide interventions. Data from public health surveillance of reported COVID-19 cases and seroprevalence surveys were used in this observational study that reports an estimated 46.9 million SARS-CoV-2 infections, 28.1 million symptomatic infections, 956,174 hospitalizations and 304,915 deaths occurred in the U.S. through Nov. 15, 2020.

Angulo, et al. (2020) sought to estimate the number of SARS-CoV-2 infections, symptomatic infections, hospitalizations, and deaths in the U.S. as of Nov. 15, 2020. In this cross-sectional study of respondents of all ages, data from 4 regional and 1 nationwide Centers for Disease Control and Prevention (CDC) seroprevalence surveys (April [n = 16 596], May, June, and July [n = 40 817], and August [n = 38 355]) were used to estimate infection underreporting multipliers and symptomatic underreporting multipliers. Community serosurvey data from randomly selected members of the general population were also used to validate the underreporting multipliers.

SARS-CoV-2 infections, symptomatic infections, hospitalizations, and deaths. The median of underreporting multipliers derived from the 5 CDC seroprevalence surveys in the 10 states that participated in 2 or more surveys were applied to surveillance data of reported coronavirus disease 2019 (COVID-19) cases for 5 respective time periods to derive estimates of SARS-CoV-2 infections and symptomatic infections, which were summed to estimate SARS-CoV-2 infections and symptomatic infections in the US. Estimates of infections and symptomatic infections were combined with estimates of the hospitalization ratio and fatality ratio to derive estimates of SARS-CoV-2 hospitalizations and deaths. External validity of the surveys was evaluated with the April CDC survey by comparing results to 5 serosurveys (n = 22 118) that used random sampling of the general population. Internal validity of the multipliers from the 10 specific states was assessed in the August CDC survey by comparing multipliers from the 10 states to all states. A sensitivity analysis was conducted using the interquartile range of the multipliers to derive a high and low estimate of SARS-CoV-2 infections and symptomatic infections. The underreporting multipliers were then used to adjust the reported COVID-19 infections to estimate the full SARS-COV-2 disease burden.

Adjusting reported COVID-19 infections using underreporting multipliers derived from CDC seroprevalence studies in April (n = 16 596), May (n = 14 291), June (n = 14 159), July (n = 12 367), and August (n = 38 355), there were estimated medians of 46 910 006 (interquartile range [IQR], 38 192 705-60 814 748) SARS-CoV-2 infections, 28 122 752 (IQR, 23 014 957–36 438 592) symptomatic infections, 956 174 (IQR, 782 509–1 238 912) hospitalizations, and 304 915 (IQR, 248 253–395 296) deaths in the US through November 15, 2020. An estimated 14.3% (IQR, 11.6%-18.5%) of the US population were infected by SARS-CoV-2 as of mid-November 2020.

The researchers conclude that SARS-CoV-2 disease burden may be much larger than reported COVID-19 cases owing to underreporting. Even after adjusting for underreporting, a substantial gap remains between the estimated proportion of the population infected and the proportion infected required to reach herd immunity. Additional seroprevalence surveys are needed to monitor the pandemic, including after the introduction of safe and efficacious vaccines.

Source: JAMA Network

2 Comments on "Researchers Suggest SARS-CoV-2 Disease Burden May Be Much Larger Due to Underreporting"

  1. 655595 867636Hi there, just became aware of your weblog through Google, and discovered that its genuinely informative. Im gonna watch out for brussels. I will appreciate if you continue this in future. Lots of folks will probably be benefited from your writing. Cheers! 821752

  2. 176160 931903Superb post. I was checking constantly this weblog and Im impressed! Very useful data specially the last part I care for such details much. I was seeking this specific details for a long time. Thank you and best of luck. 911690

Leave a comment

Your email address will not be published.


*